drugset / Trial / NCT02261116

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

NCT02261116

Phase 4 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverSingle-blindTreatment

Summary

Study to assess potential different properties of telmisartan, which due to its Vd, should result in stronger "beneficial" effects of AT1 blockade in tissues (e.g. aldosterone suppression and renin increase) plus stronger AT2 stimulation compared to candesartan

Timeline

Start
2002-04
Primary completion
2002-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Candesartan Unknown
Subject Telmisartan Other / unclassified

Indications

No indication recorded.